Latest Commercialisation News

Ionic Rare Earths (ASX: IXR) has secured $8 million through a placement to back its Belfast Plant commercialisation and US growth plans, supported by a mix of domestic and international investors including a strategic US partner.

Lithium Universe Limited has secured $900,000 through a placement with existing investors to fund working capital and progress key projects including the Brownsville Lithium Refinery PFS and innovative metal recycling technologies.

Memphasys secures exclusive Felix™ commercialisation agreement in Poland, marking its third European market entry with a two-year contract valued at approximately A$350,000.

Anson Resources has secured a conditional US$357.7 million incentive package proposal from Utah authorities, potentially easing capital and tax burdens for its Green River Lithium Project and enhancing its financial outlook.

AdAlta’s lead CAR-T therapy EW-001 has achieved a rare clinical milestone with one mesothelioma patient remaining cancer-free two years after treatment, and a second reaching one-year survival, underscoring the therapy’s potential durability in a notoriously difficult cancer.

Unith Ltd has issued over 222 million securities, raising $1 million via share placement and converting $500,000 of debt to equity, while attaching options await shareholder approval.

TG Metals has raised A$2.5 million through a placement backed by institutional investors and insiders to fund resource expansion, scoping studies, and direct shipping ore opportunities at its Western Australian gold and lithium assets.

Neurotech International has secured $4.5 million through a share placement to fund its pivotal Phase III clinical trial of NTI164 for Autism Spectrum Disorder, aiming to reach topline data readout.

Lumos Diagnostics has landed a US$767,800 purchase order for its FebriDx rapid test from PHASE Scientific, marking a key step in commercialising its FDA-approved product ahead of the US flu season.

Control Bionics has achieved FDA registration for its NeuroStrip surface EMG platform, cementing its medical device status in the US and bolstering its appeal in clinical and research markets.

Vitrafy Life Sciences reported an 80% revenue surge and halved its net loss, buoyed by US military validation and major blood network partnerships. A $32 million capital raise fuels its US commercial expansion and manufacturing scale-up.

Micro-X has named Brian Gonzales as its new CEO, initiating a strategic reset focused on medical CT technology. The company also secured $8 million in convertible note commitments to fund development and extend its financial runway through FY27.